Group 1 - The core viewpoint of the news is that Meihao Medical experienced a decline in stock price, dropping by 5.01% to 23.90 CNY per share, with a trading volume of 349 million CNY and a turnover rate of 9.16%, resulting in a total market capitalization of 13.596 billion CNY [1] - Meihao Medical, established on July 15, 2010, and listed on October 12, 2022, is located in Longgang District, Shenzhen, Guangdong Province, and specializes in the design, development, manufacturing, and sales of precision components and products for medical devices [1] - The revenue composition of Meihao Medical includes: 59.48% from home respiratory machine components, 14.61% from home and consumer electronics components, 10.33% from other medical product components, 8.16% from cochlear implant components, 5.63% from precision molds and automation equipment, 1.09% from other categories, and 0.70% from proprietary products [1] Group 2 - From the perspective of Meihao Medical's top ten circulating shareholders, Huabao Fund holds a position in the company, with its Huabao CSI Medical ETF (512170) increasing its holdings by 1.6179 million shares in the second quarter, totaling 5.694 million shares, which accounts for 3.64% of the circulating shares [2] - The Huabao CSI Medical ETF (512170), established on May 20, 2019, has a latest scale of 26.147 billion CNY, with a year-to-date return of 16.62% and a one-year return of 41.01% [2] - The fund manager of Huabao CSI Medical ETF (512170) is Hu Jie, who has a cumulative tenure of 12 years and 321 days, managing total assets of 84.336 billion CNY, with the best fund return during his tenure being 143.28% and the worst being -98.01% [2]
美好医疗股价跌5.01%，华宝基金旗下1只基金位居十大流通股东，持有569.4万股浮亏损失717.44万元